Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27313023 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TDP1TSHR | |
| SCHEMBL12040127 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TDP1TSHR | |
| SCHEMBL14261124 | 0.80 | SLC22A6 (0.38) | TDP1TSHR | |
| SCHEMBL15555383 | 0.80 | SLC22A6 (0.38) | TDP1TSHR | |
| SCHEMBL15723572 | 0.79 | PRKCA (0.33) | ALDH1A1TDP1 | |
| SCHEMBL29809464 | 0.78 | ALDH1A1 (0.46) | ALDH1A1TDP1 | |
| SCHEMBL34473867 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TDP1 | |
| SCHEMBL12707683 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TDP1TSHR | |
| SCHEMBL19574901 | 0.75 | TSHR (0.36) | TSHR | |
| SCHEMBL16139255 | 0.73 | MAPT (0.41) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107619386-B | Aromatic ring [ c ] carbazole derivative and synthesis method thereof | 湘潭大学 | 2020-10-13 | — | — | CN | disclosed |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9593129-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9499575-B2 | Synthesis of carbohydrate-based surfactants | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9296736-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140142287-A1 | SYNTHESIS OF CARBOHYDRATE-BASED SURFACTANTS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8586569-B2 | Betulonic and betulinic acid derivatives | Leunis, Jean-Claude (BE) | 2013-11-19 | — | — | US | disclosed |
| US-8569341-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20090068257-A1 | BETULONIC AND BETULINIC ACID DERIVATIVES | JEAN-CLAUDE LEUNIS (BE) | 2009-03-12 | — | — | US | disclosed |
| WO-2008052831-A2 | SOLID FORMALDEHYDE-FREE PIGMENT PREPARATIONS | EVONIK DEGUSSA GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2007141090-A1 | SOLID PIGMENT PREPARATIONS | EVONIK DEGUSSA GMBH (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142287-A1 | SYNTHESIS OF CARBOHYDRATE-BASED SURFACTANTS | DDOST, UGCG, CSGALNACT1 | ALDH1A1 4344/4885TDP1 3669/4885TSHR 2698/4885 |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | ALDH1A1 332/4885TDP1 1121/4885TSHR 4432/4885 |
| US-20080051423-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | EDNRA, EDNRB, ESRRB | ALDH1A1 820/4885TDP1 3114/4885TSHR 769/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | ALDH1A1 332/4885TDP1 1121/4885TSHR 4432/4885 |
| US-20090068257-A1 | BETULONIC AND BETULINIC ACID DERIVATIVES | BET1, PGGT1B, PAG1 | ALDH1A1 3894/4885TDP1 3552/4885TSHR 3926/4885 |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | ALDH1A1 332/4885TDP1 1121/4885TSHR 4432/4885 |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | ALDH1A1 332/4885TDP1 1121/4885TSHR 4432/4885 |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | ALDH1A1 332/4885TDP1 1121/4885TSHR 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.